TWI860279B - 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物 - Google Patents

作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物 Download PDF

Info

Publication number
TWI860279B
TWI860279B TW107133372A TW107133372A TWI860279B TW I860279 B TWI860279 B TW I860279B TW 107133372 A TW107133372 A TW 107133372A TW 107133372 A TW107133372 A TW 107133372A TW I860279 B TWI860279 B TW I860279B
Authority
TW
Taiwan
Prior art keywords
formula
amino
compound
methyltetrahydrofuran
difluoro
Prior art date
Application number
TW107133372A
Other languages
English (en)
Chinese (zh)
Other versions
TW201919649A (zh
Inventor
馬克 史密斯
克勞斯 G 克朗普
Original Assignee
美商里伯賽恩斯有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商里伯賽恩斯有限責任公司 filed Critical 美商里伯賽恩斯有限責任公司
Publication of TW201919649A publication Critical patent/TW201919649A/zh
Application granted granted Critical
Publication of TWI860279B publication Critical patent/TWI860279B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
TW107133372A 2017-09-21 2018-09-21 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物 TWI860279B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561237P 2017-09-21 2017-09-21
US62/561,237 2017-09-21

Publications (2)

Publication Number Publication Date
TW201919649A TW201919649A (zh) 2019-06-01
TWI860279B true TWI860279B (zh) 2024-11-01

Family

ID=65810030

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107133372A TWI860279B (zh) 2017-09-21 2018-09-21 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物

Country Status (12)

Country Link
US (2) US10682369B2 (enExample)
EP (1) EP3684374B1 (enExample)
JP (1) JP7299897B2 (enExample)
KR (1) KR102735678B1 (enExample)
CN (1) CN111194217B (enExample)
AR (1) AR112702A1 (enExample)
AU (1) AU2018335411B2 (enExample)
CA (1) CA3075645A1 (enExample)
IL (1) IL273398B2 (enExample)
SG (1) SG11202002431SA (enExample)
TW (1) TWI860279B (enExample)
WO (1) WO2019060740A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180200280A1 (en) * 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
AU2018335411B2 (en) * 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
EP3865535A1 (en) 2020-02-11 2021-08-18 Bosti Trading Ltd. New method of synthesis of chitosan derivatives and uses thereof
TW202144465A (zh) 2020-02-11 2021-12-01 瑞士商諾和席卓股份有限公司 合成聚葡萄胺糖衍生物之新方法及其用途
WO2022174179A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2023012333A2 (en) 2021-08-06 2023-02-09 Novochizol Sa Preparation of composite gels, polymer scaffolds, aggregates and films comprising soluble cross-linked chitosan & uses thereof
AR126678A1 (es) 2021-08-06 2023-11-01 Novochizol Sa Composiciones para el cuidado de las plantas y usos de las mismas

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (fr) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
IL126674A (en) 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
IL134233A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
CN1324250A (zh) 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
WO2000018231A1 (en) 1998-09-25 2000-04-06 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
EP1964561A1 (en) 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
AU2001261377A1 (en) 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
PL395097A1 (pl) 2001-06-11 2011-10-10 Vertex Pharmaceuticals (Canada) Incorporated Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ グループ リミテッド Hcv阻害剤としての4−(5−員)−ヘテロアリールアシルピロリジン誘導体
WO2003037893A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
ATE370137T1 (de) 2001-11-02 2007-09-15 Glaxo Group Ltd 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
US20070004669A1 (en) 2002-06-21 2007-01-04 Carroll Steven S Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172992A (zh) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的修饰的2′和3′-核苷前药
PL219609B1 (pl) * 2003-02-19 2015-06-30 Masanori Baba Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania
US20050020884A1 (en) 2003-02-25 2005-01-27 Hart Charles C. Surgical access system
WO2004096235A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 C형 간염 바이러스 ns5b 폴리머라제 억제제 결합 포켓
WO2005020884A2 (en) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
EP4032897B1 (en) 2003-05-30 2025-01-29 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
WO2005007810A2 (en) 2003-06-16 2005-01-27 Grinstaff Mark W Functional synthetic molecules and macromolecules for gene delivery
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
SI1713823T1 (sl) 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
CN101115725A (zh) 2004-12-10 2008-01-30 埃莫里大学 治疗病毒感染和异常细胞增殖的2’和3’-取代的环丁基核苷类似物
CA2618335C (en) * 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
CN101384609A (zh) * 2006-02-14 2009-03-11 默克公司 用于治疗rna依赖性rna病毒感染的氨基磷酸(核苷)(芳基)酯
AU2007215114A1 (en) 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
NZ606141A (en) 2010-07-19 2015-03-27 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
AU2012290089B2 (en) 2011-08-01 2016-09-29 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
CA2840242C (en) * 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US9108999B2 (en) 2011-12-20 2015-08-18 Riboscience Llc 2′, 4′-difluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2013142159A1 (en) * 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
JP6284547B2 (ja) * 2012-12-21 2018-02-28 アリオス バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
CN104151360B (zh) * 2013-05-14 2019-02-22 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
SG11201509424VA (en) * 2013-05-16 2015-12-30 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
US20180200280A1 (en) * 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
BR112015028765A2 (pt) * 2013-05-16 2017-07-25 Riboscience Llc derivados de nucleosídeo substituído 4'-azido, 3'-desoxi-3'-fluoro
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
WO2016164625A1 (en) * 2015-04-07 2016-10-13 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
EP3463469B1 (en) * 2016-05-27 2023-12-13 Gilead Sciences, Inc. Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication

Also Published As

Publication number Publication date
IL273398B2 (en) 2025-02-01
WO2019060740A1 (en) 2019-03-28
US11351186B2 (en) 2022-06-07
EP3684374B1 (en) 2025-07-30
JP7299897B2 (ja) 2023-06-28
TW201919649A (zh) 2019-06-01
AR112702A1 (es) 2019-11-27
EP3684374A4 (en) 2021-06-16
CN111194217B (zh) 2024-01-12
KR20200056420A (ko) 2020-05-22
KR102735678B1 (ko) 2024-11-27
US20190231804A1 (en) 2019-08-01
US20210046100A1 (en) 2021-02-18
CN111194217A (zh) 2020-05-22
EP3684374A1 (en) 2020-07-29
IL273398A (en) 2020-05-31
CA3075645A1 (en) 2019-03-28
IL273398B1 (en) 2024-10-01
SG11202002431SA (en) 2020-04-29
JP2020534374A (ja) 2020-11-26
AU2018335411B2 (en) 2024-06-27
US10682369B2 (en) 2020-06-16
AU2018335411A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
AU2012357940B2 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
AU2012357986B2 (en) 4'-Azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
EP2996695B1 (en) 4'-fluoro-2'-methyl substituted nucleoside derivatives
TWI860279B (zh) 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物
US20210369755A1 (en) 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
HK1199037B (en) 4'-azido-3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
HK1199036B (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
HK1200836B (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
HK1219900B (zh) 4’-氟-2’-甲基取代的核苷衍生物
RS56101B1 (sr) 4'-azido-3'-fluoro supstituisani derivati nukleozida kao inhibitori hcv rnk replikacije